A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

By S. Knapper, A. Burnett, Timothy Littlewood, W. J. Kell, Sam Agrawal, R. Chopra, Richard E. Clark, M. Levis, D. Small. Blood, 2004

941 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/d6d1c132cfc770b14828d7f46abab743d4bd22d7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Levi Waldron
2. Benjamin L. Ebert
3. Igor Jurisica

In Hematology

1. Benjamin L. Ebert
2. J. Dick

Citations in the corpus

• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. (2008, neutral): “M5 166 117 (71) 11 (7) 29 (17) 9 (5) — 143 73 (51) 70 (49) —”
• Stem cell gene expression programs influence clinical outcome in human leukemia (2011, background): “Recently, the combined mutational status of FLT3 and NPM1 has been found to designate low molecular risk (NPM1mut FLT3wt; LMR) and high molecular risk (FLT3ITD or NPM1wt FLT3wt; HMR) group”
• Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). (2006, neutral): “Median platelet count, 109/L (range) 68 (7-302)* 56 (3-514) 47 (5-372) 46 (4-1430)”
• Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia (2012, neutral): “1005-010 M 52 713, HDAC, mitoxantrone and etoposide 46,XY,t(4;12)(q26;p11.”